Cancers
Anthracycline-Free FLA-VEN with or Without Midostaurin in Newly Diagnosed Intermediate- and Adverse-Risk AML: A Single-Center Retrospective Study
By Sinem Namdaroğlu, Merve Kakci, Berrak Şenol and 6 others.
Abstract
Background
Anthracycline-containing intensive chemotherapy remains a standard frontline approach for medically fit patients with acute myeloid leukemia (AML). We retrospectively evaluated an exploratory anthracycline-sparing regimen combining fludarabine, cytarabine, and venetoclax (FLA-VEN), with midostaurin added in FLT3-mutated cases, in selected patients with intermediate- or adverse-risk AML.
